Cabaletta Bio Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
| Cabaletta Bio, Inc. | ||
| Date: March 21, 2024 | By: | /s/ Steven Nichtberger |
|---|---|---|
| Steven Nichtberger, M.D. | ||
| Chief Executive Officer and President | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Steven Nichtberger | Director, Chief Executive Officer and President | March 21, 2024 |
| Steven Nichtberger, M.D. | (Principal Executive Officer) | |
| /s/ Anup Marda | Chief Financial Officer | March 21, 2024 |
| Anup Marda | (Principal Financial and Accounting Officer) | |
| /s/ Catherine Bollard | Director | March 21, 2024 |
| Catherine Bollard, M.D. | ||
| /s/ Scott Brun | Director | March 21, 2024 |
| Scott Brun, M.D. | ||
| /s/ Richard Henriques | Director | March 21, 2024 |
| Richard Henriques | ||
| /s/ Mark Simon | Director | March 21, 2024 |
| Mark Simon | ||
| /s/ Shawn Tomasello | Director | March 21, 2024 |
| Shawn Tomasello | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.